NuVasive (NUVA) Reports In-Line Q1 EPS; Guides Relativity In-Line

NuVasive (NASDAQ: NUVA) reported Q1 EPS of $0.38, in-line with the analyst estimate of $0.38. Revenue for the quarter came in at $250 million versus the consensus estimate of $250.8 million.

"NuVasive is off to a solid start to the year, with our International business exceeding our expectations, and we saw momentum building in our U.S. business as we exited the quarter," said Gregory T. Lucier, chairman and chief executive officer of NuVasive. "We are on track to deliver non–GAAP operating profit margin expansion of at least 100 basis points in 2017, reflecting our continued focus on operational efficiencies and the ramp up of our in-house manufacturing facility. Coupled with several innovative product and systems launches planned for 2017, including LessRay designed for radiation reduction, RELINE Trauma system, expandable cages and UNYTE system for complex fractures, we anticipate strong revenue acceleration for the balance of the year."

GUIDANCE:

NuVasive sees FY2017 EPS of $2.00-$2.02. NuVasive sees FY2017 revenue of $1.065-1.07 billion.

For earnings history and earnings-related data on NuVasive (NUVA) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• Is Treasury selloff a major issue for stock market bulls?